Navigation Links
Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
Date:2/10/2009

SHANGHAI, China, Feb. 10 /PRNewswire-Asia/ -- Sundia MediTech, a CRO company based in Shanghai, China and Xcovery, a company based in Florida, U.S.A. jointly announced their 2 year collaborative success in new drug discovery at IBC's BioProcess International Conference yesterday in San Diego, USA. So far their collaboration has achieved 4 pre-clinic candidates, with 2 more candidates to be identified within the next 3 months. Dr. Xiaochuan Wang, CEO of Sundia MediTech Company and Ms. Teri A. Swift, Vice President for Business Development of Xcovery, made the announcement together.

Both of Xcovery's founders are legendary figures in the U.S. biotech industry. Mr. Sherry Snyder, CEO of the company, is a pioneer and leader of this industry with significant contributions towards its development. In his professional career, he founded different companies including the well-known biotech company Genzyme. Company CSO Dr. Chris Liang earned his reputation as a leading drug discovery expert from his leadership and contribution to the discovery of Sutent, Pfizer's leading anti-cancer drug. In recent years, he continued to achieve multiple successes in drug discovery.

In 2006, Mr. Snyder invited Dr. Liang to start a new drug discovery company Xcovery. They abandoned the old model of using internal resources to do research and utilized almost 100% CRO resources for R&D work instead. After evaluating many CRO companies, amongst more than 10 in China they selected Sundia as their CRO service provider. "We are honored to have the opportunity of providing R&D service to Xcovery," said Sundia's CEO Dr. Xiaochuan Wang. "It is Sundia's objective to provide high end CRO service with rich R&D content to our clients. We have successfully identified 12 new pre-clinic candidates for our client companies from different countries."

According to Dr. Chris Liang, the result of Xcovery's collaboration with Sundia was much better than they expected. They got 4 (possibly 6) pre-clinic products in merely 2.5 years. Compared to their initial target, the research efficiency and outcome is ten folds higher. Mr. Snyder commented: "The value of this collaboration is not only in the pre-clinic candidates we've generated, but more importantly it sets a precedent as the most efficient and economical model for new drug discovery."

About the Companies:

Xcovery is a new biotechnology company spun out from The Scripps Research Institute by Sherry Snyder (CEO) and Chris Liang (CSO), with the support of several prominent academic partners. Xcovery develops next generation kinase therapeutics for cancer and inflammatory diseases more rapidly and economically than current approaches.

Sundia MediTech Company was founded in Shanghai in 2004 by a group of veterans of the US pharmaceutical industry to provide drug discovery and pharmaceutical development CRO services to clients worldwide. Over the past 5 years, Sundia has built a strong reputation as a leading CRO Company in China.


'/>"/>
SOURCE Sundia MediTech Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
2. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
3. Weed Science Society of America Announces Winners in Annual Scientific Awards Program
4. Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
5. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
6. LAB Research announces changes to its Board of Directors
7. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW BITTER BLOCKERS
8. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
9. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
10. Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ... and clinical data from its phase 1/2 tendon repair study ... fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The clinical ... at 6 months and showed no serious adverse events related ...
(Date:3/28/2017)... ... ... Executive search firm, Slone Partners, announces the placement of ... distinguished life sciences expert with a proven track record in strategic global business ... of services related to laboratory testing and analysis for the pharmaceutical, medical device, ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a ... disease and more through a single-cell precision engineering platform, today announced it has ... in the laboratory of Dr. James Heath at the California Institute of ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small cell ... with limited tumor content in a large background of normal or wild type ... need for reliable detection of low abundance somatic mutations, particularly in small specimens ...
Breaking Biology Technology:
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):